RAPIDNCT05979545
EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics
At risk: Primary completion moved 12 months later, primary endpoint(s) modified, and 1 more.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Oct 31, 2026 to Oct 31, 2027 Show 7 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 95 words
- Enrollment reduced: 1900 → 1526 participants
- Trial sites expanded: 4 → 21 locations
- Study completion pushed from Dec 31, 2026 to Dec 31, 2027
- Secondary endpoints: 5 to 21
- Study description expanded, about 64 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Oct 1, 2023 to Dec 12, 2023
- Secondary endpoints revised (5)
- Study title shortened, about 25 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (21)
Show 16 moreShow less
Arms and interventions
Rapid microbiological diagnostics using the BioFire BCID2 Panel for bloodstream infections or BioFire FilmArray Pneumonia/Pneumonia Plus Panel for respiratory infections, combined with locally adapted antimicrobial stewardship and early targeted antibiotic therapy. Samples from patients randomised to the intervention arm will undergo the BioFire FilmArray systems. Patients will be then administered with the study drug, ceftazidime-avibactam when Pseudomonas aeruginosa or carbapenemase producing Enterobacterales detected. Appropriate antibiotic must be administered according to predefined antibiotic stewardship guidelines within 24 hours of the Gram stain being performed on the index specimen.
Standard-of-care microbiological diagnostics and antibiotic treatment according to local clinical practice and treating physician discretion. Patients randomised to the control arm, will have samples analysed by clinical microbiology laboratories using standard of care diagnostics. Antibiotics treatment will be administered as per usual institutional practice from hospital supplies.
Diagnostic tests: Rapid Diagnostics
Sites
21 sites in 7 countries
Malaysia 5, South Korea 4, Taiwan 4, Thailand 4, Singapore 2, India 1, Turkey (Türkiye) 1